title: Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin.
abstract: BACKGROUND
  Aspirin effectively reduces the incidence of secondary vascular occlusive events in only 25% of patients. Low-dose aspirin as currently used blocks platelet production of prothrombotic thromboxane A2 and allows endothelial synthesis of antithrombotic prostacyclin. This regimen minimizes gastrointestinal toxicity. We previously showed that intact erythrocytes markedly enhance platelet reactivity. Therefore we investigated whether supplementation of low-dose aspirin with a single high dose at 2-week intervals could more effectively block erythrocyte promotion of platelet reactivity.
  
  
  RESULTS
  Effects of different aspirin regimens on erythrocyte enhancement of platelet reactivity in normal volunteers were measured with the use of an assay that evaluates both platelet activation and recruitment. After 15 days of daily ingestion of 50 mg aspirin, reactivity of platelets alone was inhibited. However, erythrocyte promotion of platelet activation and recruitment was only inhibited by approximately 50% and persisted in the total absence of thromboxane synthesis. In contrast, if 50 mg/d aspirin was preceded by a single loading dose of 500 mg aspirin, the erythrocyte prothrombotic effect was strongly inhibited (approximately 90%) for 2 to 3 weeks. However, over time, erythrocytes "escaped" from this inhibition, and once again became prothrombotic, even on a daily regimen of 50 mg aspirin.
  
  
  CONCLUSIONS
  For clinical purposes, we recommend a loading dose of aspirin (500 mg), followed by daily administration of 50 mg. The loading dose should be repeated at 2-week intervals. This regimen blocks recovery of the erythrocyte capacity to promote platelet reactivity and may amplify the therapeutic potential of aspirin in cardiovascular disease.
authors.affiliation: Research Center, University Hospital La Fé, Valencia, Spain.
authors.forename: M T
authors.initials: MT
authors.lastname: Santos
authors.forename: J
authors.initials: J
authors.lastname: Valles
authors.forename: J
authors.initials: J
authors.lastname: Aznar
authors.forename: A J
authors.initials: AJ
authors.lastname: Marcus
authors.forename: M J
authors.initials: MJ
authors.lastname: Broekman
authors.forename: L B
authors.initials: LB
authors.lastname: Safier
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001792:Blood Platelets / Q000378:metabolism / Q000502:physiology*; D004334:Drug Administration Schedule; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism; D013931:Thromboxanes / Q000096:biosynthesis; D013997:Time Factors
chemical_list: D013931:Thromboxanes; D012701:Serotonin; D001241:Aspirin